Gangtok Chronicle

Delveinsight Business Research LLP

DelveInsight’s “Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Pulmonary Hypertension, historical and forecasted epidemiology as well as the Pulmonary Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Pulmonary Hypertension market report provides current treatment practices, emerging drugs, Pulmonary Hypertension market share of the individual therapies, and current and forecasted Pulmonary Hypertension market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Pulmonary Hypertension treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pulmonary Hypertension market.

Some of the key facts of the Pulmonary Hypertension Market Report

• The secondary research on the growth rate by analysts at DelveInsight across the 7MM population for states that in the US the growth rate of the patient pool in the forecast period (2022-2032) is 0.78%. The EU-5 on the other hand reports a population growth rate of 0.18%.

• CPH has a significant prevalence among the old population. Secondary findings show that the US has 17,363,064 total prevalent cases of PH in 2019.

 Got queries? Click here to know more about the Pulmonary Hypertension Market Landscape

Pulmonary Hypertension Overview

Pulmonary hypertension encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance. Pulmonary hypertension is a progressive disease with treatment focused on the management of symptoms and treatment of underlying diseases. Some common underlying causes of pulmonary hypertension include high blood pressure in the lungs’ arteries due to some types of congenital heart disease, connective tissue disease, coronary artery disease, high blood pressure, liver disease (cirrhosis), blood clots to the lungs, and chronic lung diseases like emphysema. Genetics also plays a role.

Pulmonary hypertension can happen in association with many other diseases, such as lung disease and heart disease. Heart failure is common in pulmonary hypertension.

ØThe symptoms of pulmonary hypertension during the initial stage of the disease are common to many other medical conditions (e.g., difficulty breathing, fatigue). This often results in a delayed diagnosis until more severe symptoms arise, such as dizziness, chest pain, ankle swelling, or feeling the heart race or pound (palpitations).

 Pulmonary Hypertension Epidemiology Insights

• Corris & Seeger (2020) found that the true global burden of pulmonary hypertension is not yet known, but it is certainly underestimated. It should no longer be considered as a rare disease and, for several important reasons, its impact on global health needs to be urgently assessed.

• World Health Organization (WHO) has organized PH into 5 classifications according to the cause, and classifications. Group 1 primary pulmonary hypertension, or pulmonary arterial hypertension (PAH). Among this group, idiopathic PAH is the most common condition, with other causes such as toxin-induced, connective tissue disorders, and other related conditions being less prevalent. Group 2 involves PH due to left heart disease, which is the most common cause of PH. Group 3 PH is due to lung diseases such as COPD and interstitial lung disease. Chronic pulmonary thromboembolism causes group 4 PH, and group 5 PH is due to unclear or multifactorial causes

• The secondary research on the growth rate by analysts at DelveInsight across 7MM population for CPH states that in the US the growth rate of PH patient pool in the forecast period (2022-2032) is 0.78%. The EU-5 on the other hand reports a population growth rate of 0.18%.

 Pulmonary Hypertension Epidemiology Segmentation

• Total Pulmonary Hypertension prevalent cases 

• Total Pulmonary Hypertension group-specific prevalent cases 

• Total Pulmonary Hypertension age specific prevelant cases 

• Total Pulmonary Hypertension gender specific prevelant cases 

Pulmonary Hypertension Market Outlook

The Pulmonary Hypertension market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pulmonary Hypertension market trends by analyzing the impact of current Pulmonary Hypertension therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Pulmonary Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pulmonary Hypertension market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pulmonary Hypertension market in 7MM is expected to witness a major change in the study period 2019-2032.

 Learn more by requesting for sample @ Pulmonary Hypertension Market Trends

Pulmonary Hypertension Key Companies 

• Attgeno AB

• Cereno Scientific AB

• Bial – Portela C S.A.

• Liquidia Technologies

• Bellerophon Therapeutics

• And many others

 Pulmonary Hypertension Therapies

• Supernitro (PDNO)

• CS1

• Zamicastat (BIA 5-1058)

• Yutrepia (LIQ861 Inhaled Treprostinil)

• INOpulseAnd many others 

 Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of Pulmonary Hypertension  

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.   Pulmonary Hypertension Emerging Therapies

7.  Pulmonary Hypertension Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Pulmonary Hypertension Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Click here to read more about Pulmonary Hypertension Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/